What is Genesis Biosystems?
Genesis Biosystems stands as a global leader in developing innovative aesthetic technologies and comprehensive skin rejuvenation solutions. The company's extensive product portfolio is engineered to enable practitioners to tailor procedures for their clientele, with its flagship product, DermaFrac, recognized for delivering exceptional results in skin treatment. This efficacy has cemented DermaFrac's status as a preferred choice among both practitioners and patients. Genesis Biosystems places a strong emphasis on product safety, proven efficacy, and superior quality, primarily serving aesthetic practitioners and their patients who are seeking advanced and effective skin care. The company's global reach is supported by dedicated training and support services aimed at optimizing treatment outcomes and enhancing overall skin health.
How much funding has Genesis Biosystems raised?
Genesis Biosystems has raised a total of $114K across 1 funding round:
Debt
$114K
Debt (2021): $114K with participation from PPP
What's next for Genesis Biosystems?
With the recent influx of capital, Genesis Biosystems is strategically positioned for accelerated growth and further innovation in the aesthetic technology market. The substantial backing indicates a strong belief in the company's business model and its capacity to scale operations and expand its product offerings. This investment will likely fuel research and development initiatives, potentially leading to new product launches or enhancements to existing technologies. Furthermore, the financing may support market expansion efforts, both domestically and internationally, allowing Genesis Biosystems to reach a broader customer base and solidify its leadership in skin rejuvenation solutions. The company's focus on empowering practitioners and delivering client-centric results suggests a continued commitment to maintaining its competitive edge through technological advancement and superior service.
See full Genesis Biosystems company page
